Key facts
- Alixia’s last known valuation is $22.5M (Jul 2024).
- It has raised $3.8M across 1 recorded rounds; the latest was Seed Round ($1.8M) in Jul 2024.
- Notable investors include Y Combinator, SOSV, Gaingels, StartX (US), Endless Frontier Labs — 9 tracked in total.
- Alixia has filed 1 Form D with the SEC, most recently Jul 2024 ($1.8M sold to 19 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Alixia
Funding rounds
1 roundsAbout Alixia
Developer of mitochondria-targeting therapeutics designed for drug discovery. The company's mitochondrion regulators checkpoint system reduces chronic inflammation and improves metabolism by stimulating cells to declutter dysfunctional mitochondria, enabling physicians to help patients boost cognitive health, recover faster from physical activities, and reduce joint pain.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2018
- Employees
- 6
- Website
- alixia.com/
- Ownership
- Privately Held (backing)
Alixia doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Alixia shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Alixia in its N-PORT filings yet. We sweep new filings monthly.